Separation of two active ingredients in tablets does not validate their measurement in blood.
The method-development study used reverse-phase HPLC with diode-array detection and experimental optimization. It separated clonazepam and escitalopram, assessed pharmaceutical validation characteristics and examined degradation-product separation. Marketed tablets were assayed near their labeled content.
The intended matrix was a dosage form, not a forensic specimen. Biological extraction, matrix effects, metabolite interference and lower clinical concentration ranges require separate validation. A retention time under one chromatographic system is not a universal identity marker.
For an analytical opinion, match the validation to the actual question and specimen. Tablet content uniformity cannot establish a patient’s ingestion, circulating concentration or impairment. The paper supports a pharmaceutical assay without proving that an unrelated clinical laboratory’s result is accurate or specific.
Source reviewed: Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC DAD Method (PMC9268709). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: Bromazolam Tablet Study Found Wide Dose Variation and Heavily Mixed Death Cases.